| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Euphorbia factor L7b targets the NF-κB signaling pathway and induces apoptosis in cancer cells. Its anti-inflammatory effects are attributed to modulation of key signaling pathways. As a natural diterpenoid from Euphorbia pekinensis, a plant used in traditional herbal medicine, its cytotoxic effects suggest additional targets in cancer cells.
|
|---|---|
| ln Vitro |
In vitro studies of Euphorbia factor L7b have demonstrated anti-inflammatory and cytotoxic effects. The compound modulates signaling pathways such as NF-κB and induces apoptosis. However, specific potency data such as IC₅₀ values against particular cell lines are not detailed in the available literature.
|
| ln Vivo |
Specific in vivo activity data for Euphorbia factor L7b are not available in the consulted sources. As a natural product with anti-inflammatory and cytotoxic effects, it may have potential in vivo efficacy in models of cancer and inflammation. However, no systematic in vivo studies have been reported.
|
| Enzyme Assay |
Typical in vitro assays for Euphorbia factor L7b include anti-inflammatory assays measuring NO production in LPS-stimulated macrophages. Cytotoxicity assays are performed using cancer cell lines treated with the compound for 48-72 hours, and cell viability is assessed by MTT or similar assays. NF-κB signaling is assessed by reporter gene assays or Western blot.
|
| Cell Assay |
Cellular assays for Euphorbia factor L7b typically involve treating cancer cell lines or macrophages with the compound at concentrations ranging from 1-100 µM. Cell viability is assessed by MTT assay. Apoptosis is evaluated by Annexin V/PI staining and caspase activity measurements. NF-κB activation is assessed by Western blot or reporter gene assays.
|
| Animal Protocol |
In vivo animal experiments for Euphorbia factor L7b have not been reported in the available literature. For potential anticancer or anti-inflammatory studies, typical animal models such as xenograft or inflammation models could be employed, but no specific protocols have been established.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Euphorbia factor L7b are not available in the consulted sources. As a diterpenoid with a molecular weight of 580.67 g/mol, it would be expected to have moderate lipophilicity. Detailed ADME parameters have not been characterized.
|
| Toxicity/Toxicokinetics |
No toxicological data are available for Euphorbia factor L7b in the consulted sources. As a natural product from Euphorbia pekinensis, a plant used in traditional medicine, it is generally considered to have low toxicity, but comprehensive toxicological studies have not been reported.
|
| References | |
| Additional Infomation |
It has been reported that plants in the Euphorbia genus contain the Euphorbia factor L7b, and relevant data are available for reference.
Euphorbia factor L7b is a natural diterpenoid (isolathyrolditerpene) from Euphorbia pekinensis Rupr. It exhibits anti-inflammatory and cytotoxic effects through NF-κB modulation and apoptosis induction. It is a research compound for studying cancer and inflammation. It is not approved for any clinical indication. |
| Molecular Formula |
C33H40O9
|
|---|---|
| Molecular Weight |
580.67
|
| Exact Mass |
580.267
|
| CAS # |
93550-95-9
|
| PubChem CID |
156599174
|
| Appearance |
White to off-white solid
|
| LogP |
4.782
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
42
|
| Complexity |
1170
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC1CC2(C(C1OC(=O)C3=CC=CC=C3)C(C(=CCC4C(C4(C)C)C=C(C2=O)C)COC(=O)C)OC(=O)C)OC(=O)C
|
| InChi Key |
ARUXHDLPKVRONO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C33H40O9/c1-18-15-26-25(32(26,6)7)14-13-24(17-39-20(3)34)29(40-21(4)35)27-28(41-31(38)23-11-9-8-10-12-23)19(2)16-33(27,30(18)37)42-22(5)36/h8-13,15,19,25-29H,14,16-17H2,1-7H3
|
| Chemical Name |
[1,11-diacetyloxy-10-(acetyloxymethyl)-3,6,6,14-tetramethyl-2-oxo-13-tricyclo[10.3.0.05,7]pentadeca-3,9-dienyl] benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7221 mL | 8.6107 mL | 17.2215 mL | |
| 5 mM | 0.3444 mL | 1.7221 mL | 3.4443 mL | |
| 10 mM | 0.1722 mL | 0.8611 mL | 1.7221 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
